RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

Overview of attention for article published in International Journal of Nanomedicine, September 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 11 publications that cite this research output.

11

The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.

A cathepsin B-sensitive gemcitabine prodrug for enhanced pancreatic cancer therapy

Article in Journal of Pharmaceutical Sciences (March 2024)

Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments

Article in Advanced Drug Delivery Reviews (March 2023)

Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells

Article in Pharmaceuticals (April 2022)